“On the other hand, participating in a combo trial with Remdesivir would have led people to believe (in error( that Rem actually had some benefit, off of LLMab's efficacy.”

This is actually false. Remdesevir is unfortunately the SOC and the trial would’ve consisted of two arms, LL/remdesevir compared to remdesevir (the SOC). Therefore, the benefit of leronlimab would’ve been very clear and added to the growing science that leronlimab may be a monotherapy for the S/C population.